< Back to previous page
Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
21 - 30 of 64
- Translational research-oriented technology platform for single cell analysisFrom1 May 2020 → TodayFunding: BOF - scientific equipment program
- Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsiesFrom1 Jan 2020 → TodayFunding: H2020 - European Institute of Innovation and Technology
- Implementation of Artificial Intelligence in Colonoscopic DiagnosticsFrom1 Nov 2019 → TodayFunding: FWO Strategic Basic Research Grant
- Microbiota modulation strategies in Inflammatory Bowel Disease managementFrom1 Oct 2019 → 1 Oct 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- “Predicting response to therapy in inflammatory bowel diseases ”From23 Sep 2019 → 23 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic ConditionsFrom1 Sep 2019 → TodayFunding: H2020 - European Institute of Innovation and Technology
- Perianal fistulas in Crohn’s disease: new insights on pathogenesis, diagnosis and treatment.From1 Aug 2019 → 1 Aug 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Treatment options in IBDFrom11 Jan 2019 → 31 Oct 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Exploration and preclinical validation of myeloid cell pathways as novel targets and biomarkers for fibrosis development in IBDFrom1 Jan 2019 → 31 Dec 2022Funding: FWO Strategic Basic Research (SBO)
- Identification and Validation of a Predictive Serological Biomarker Signature for Therapeutic Response to Anti-TNF, Vedolizumab, and UstekinumabFrom1 Dec 2018 → 30 Nov 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 1016
- A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.(2024)
Authors: Séverine Vermeire
Pages: 415 - 427 - Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study(2024)
Authors: Séverine Vermeire, Jeroen Raes, Noël Knops
- Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.(2024)
Authors: Séverine Vermeire
Pages: 403 - 412 - Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply.(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1007 - 1008 - Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.(2024)
Authors: Séverine Vermeire
Pages: 404 - 415 - Crohn's disease.(2024)
Authors: Séverine Vermeire
Pages: 1177 - 1191 - Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study(2024)
Authors: Séverine Vermeire
- A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State(2024)
Authors: Tom Hillary, Maya Imbrechts, Thomas Vanassche, Maria Garmyn, Séverine Vermeire
- Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 723 - 724 - Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.(2024)
Authors: Bram Verstockt, Marc Ferrante, João Guedelha Sabino, Jeroen Raes, Séverine Vermeire
Pages: 483 - 495
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)